Caplin Point likely to end FY20 with 10% revenue from the US
Caplin Point Laboratories received the US Food and Drug Administration. (USFDA) nod for its generic medicine for blood pressure. The product is of strategic importance to the company because of some of the other drugs that it has in similar therapeutic segments. “This is a product that we filed for approval last year. We have…